Aktuellt
SENASTE
Redeye initiates coverage of SenzaGen, a Swedish commercial-stage MedTech company offering high-performance in-vitro technology tests that are set to capitalize on the trend toward animal-free testing in cosmetics, medical devices, chemicals, and pharmaceutical industries. Its updated growth-oriented commercial strategy, driven by an increased effort for acquisitions, offers a compelling case with 63% upside to our Base Case.
LÄS MER
